
    
      Single-center, randomized, open-label, single-dose, three-way-crossover trial is designed to
      assess the safety and tolerability of TNX-102 2.4 mg (a dose based on the results of a
      previous Phase 2a, proof-of-concept study - VPI-CY-0001.1) and to compare the rate and extent
      of absorption of TNX-102 2.4 mg and cyclobenzaprine 5 mg tablets under fasting or fed
      conditions.
    
  